Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis

Diagnostics, Journal Year: 2024, Volume and Issue: 14(6), P. 621 - 621

Published: March 14, 2024

While ground-glass opacity, consolidation, and fibrosis in the lungs are some of hallmarks acute SAR-CoV-2 infection, it remains unclear whether these pulmonary radiological findings would resolve after symptoms have subsided. We conducted a systematic review meta-analysis to evaluate chest computed tomography (CT) abnormalities stratified by COVID-19 disease severity multiple timepoints post-infection. PubMed/MEDLINE was searched for relevant articles until 23 May 2023. Studies with COVID-19-recovered patients follow-up CT at least 12 months post-infection were included. evaluated short-term (1–6 months) long-term (12–24 follow-ups (severe non-severe). A generalized linear mixed-effects model random effects used estimate event rates findings. total 2517 studies identified, which 43 met inclusion (N = 8858 patients). Fibrotic-like changes had highest rate (0.44 [0.3–0.59]) (0.38 [0.23–0.56]) follow-ups. meta-regression showed that over time decreased any abnormality (β −0.137, p 0.002), opacities −0.169, < 0.001), increased honeycombing 0.075, 0.03), did not change fibrotic-like changes, bronchiectasis, reticulation, interlobular septal thickening (p > 0.05 all). The severe subgroup significantly higher bronchiectasis 0.02), reticulation 0.001) when compared non-severe subgroup. In conclusion, significant remained up 2 years post-COVID-19, especially disease. Long-lasting post-SARS-CoV-2 infection signal future public health concern, necessitating extended monitoring, rehabilitation, survivor support, vaccination, ongoing research targeted therapies.

Language: Английский

---

The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view

Biomedicines, Journal Year: 2024, Volume and Issue: 12(3), P. 639 - 639

Published: March 13, 2024

SARS-CoV-2 infection is a significant health concern that needs to be addressed not only during the initial phase of but also after hospitalization. This consequence various pathologies associated with long COVID-19, which are still being studied and researched. Lung fibrosis an important complication found in up 71% patients discharge. Our research based on scientific articles indexed PubMed; selection process, we used following keywords: “lung fibrosis”, “fibrosis mediators”, predictors”, “COVID-19”, “SARS-CoV-2 infection”, “long COVID-19”. In this narrative review, aimed discuss current understanding mechanisms initiation progression post-COVID-19 lung (PC-19-LF) risk factors for its occurrence. The pathogenesis pulmonary involves mediators such as TGF-β, legumain, osteopontin, IL-4, IL-6, IL-13, IL-17, TNF-α, Gal-1, Gal-3, PDGF, FGFR-1. key cellular effectors involved COVID-19 macrophages, epithelial alveolar cells, neutrophils, fibroblasts. main pathways include hypoxemia-induced fibrosis, macrophage-induced viral-fibroblast interaction-induced fibrosis.

Language: Английский

---

The impact of lifting COVID-19 restrictions on influenza transmission across countries

Advances in Continuous and Discrete Models, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 31, 2025

Language: Английский

---

Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach

Diseases, Journal Year: 2024, Volume and Issue: 12(5), P. 95 - 95

Published: May 6, 2024

Long COVID affects both children and adults, including subjects who experienced severe, mild, or even asymptomatic SARS-CoV-2 infection. We have provided a comprehensive overview of the incidence, clinical characteristics, risk factors, outcomes persistent COVID-19 symptoms in encompassing vulnerable populations, such as pregnant women oncological patients. Our objective is to emphasize critical significance adopting an integrated approach for early detection appropriate management long COVID. The incidence severity can significant impact on quality life patients course disease case pre-existing pathologies. Particularly, fragile patients, presence PASC related significantly worse survival, independent from vulnerabilities treatment. It important try achieve recognition management. Various mechanisms are implicated, resulting wide range presentations. Understanding specific factors involved crucial tailoring effective interventions support strategies. Management approaches involve biopsychosocial assessments treatment comorbidities, autonomic dysfunction, well multidisciplinary rehabilitation. overall one gradual improvement, with recovery observed majority, though not all, As research long-COVID continues evolve, ongoing studies likely shed more light intricate relationship between chronic diseases, status, cardiovascular psychiatric disorders, effects This information could guide healthcare providers, researchers, policymakers developing targeted interventions.

Language: Английский

---

Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain

Environmental Research, Journal Year: 2022, Volume and Issue: 215, P. 114252 - 114252

Published: Sept. 10, 2022

Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data (VE) in comorbid patients are limited. We aimed to estimate booster dose VE against SARS-CoV-2 infection severity general population patients. A retrospective test-negative control study was undertaken Galicia-Spain (December 2020–November 2021). 95% confidence interval (CI) were estimated using multivariate logistic regression models. 1,512,415 (94.13%) negative 94,334 (5.87%) positive test results included. associated with substantially higher protection than vaccination without a [VEboosted = 87% (95%CI: 83%; 89%); VEnon-boosted 66% 65%; 67%)]. The high observed all ages, but more pronounced subjects older 65 years. analyzed mixed boosted non-boosted individuals considerable obtained [VE: hospitalization 72% 68%; 75%); intensive care unit administration 83% 78%; 88%), in-hospital mortality 53%; 75%)]. Boosted protected those who non-boosted. This wide range major diseases including cancer (81% versus 54%), chronic obstructive pulmonary disease (84% 61%), diabetes 65%), hypertension (82% 65%) obesity (91% 67%), among others. increases

Language: Английский

---

Prevalence and risk factors of long COVID-19 persisting for 2 years in Hainan Province: a population-based prospective study

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 2, 2025

Coronavirus disease 2019 (COVID-19) can lead to persistent symptoms, sequelae, and other medical complications that may last for weeks or months after recovery. The aim of the study is assess prevalence risk factors long COVID-19 persisting 2 years in Hainan Province, China, aid its recognition, prevention, treatment. Between July August 2022, 960 individuals with confirmed SARS-CoV-2 infection Hainan, were recruited. An epidemiological questionnaire was conducted via phone interviews participants' recovery status years. Among participants, 120 patients (12.5%) experienced at least one complication. most common symptoms cough (33.3%, 40/120), followed by fatigue (25.9%, 31/120), hair loss (23.3%, 28/120), dizziness (20.8%, 25/120). Independent included age over 65, moderate severe infection, chronic diseases, irregular diet, late sleeping, anxiety, fewer than vaccinations (p < 0.05). While infected fully recover, approximately 12.5% experience intermediate long-term effects. This first identify incidence associated longest follow-up time, providing valuable insights timely restoration pre-COVID-19 health.

Language: Английский

---

Edible Mushroom and Respiratory Diseases

Reference series in phytochemistry, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 39

Published: Jan. 1, 2025

Language: Английский

---

Outcomes of Severe Covid-19 Among Patients Who Did and Did Not Receive Tocilizumab: A Two-year Prospective Cohort Study

Published: Jan. 20, 2025

Evidence about long-term effects of tocilizumab (TCZ) treatment after COVID-19 is sparse. This study explored COVID-19-related outcomes over a two-year period among people who received TCZ and those did not. Patients were recruited from two healthcare centers in Serbia, March 2021 to December 2022. Demographic, clinical, laboratory data collected hospital records. Outcomes years follow-up, such as post-COVID syndrome (PCS) mortality, retrieved records or through telephone calls. Cumulative mortality the cohort (150; 32.8% patients) was 20.6%, non-TCZ (307 patients; 67.2%) 24.7%. In recipients there lower cumulative incidence PCS (3.4% vs. 9.9%, p = 0.018). Predictors both cohorts included age, receiving intensive care unit treatment, having insulin-dependent diabetes, elevated C-reactive protein creatinin kinase on admission. addition, chest pain admission, being smoker, pre-existing respiratory diseases cancer along with high aspartate aminotranspherase admission predictive higher cohort. had rates follow-up. suggests that has potential health benefits for hospitalized COVID-19.

Language: Английский

---

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Abstract Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) not been sufficiently validated. A retrospective, multicenter cohort study involving 10 hospitals Henan Province was performed to assess inpatients with CRDs (Clinical Trial Registration Number: NCT06349655). Azvudine recipients control group were matched at 1:1 ratio using propensity scores. The clinical outcomes (all‐cause death composite disease progression) analyzed Kaplan‒Meier Cox regression analyses, additional subgroup sensitivity analyses performed. Eighteen features included construct nomogram for predicting survival CRDs. Out 37,606 hospitalized patients, 1462 controls analysis. results multivariate demonstrated that contrast controls, use associated decreased risk all‐cause pre‐existing (log‐rank: p = .012; HR: 0.73; 95% CI: 0.553‒0.956); but significantly different terms progression .82; 1.15; 0.948‒1.383). An analysis subgroups three appraisals validate above outcomes. number type adverse events acceptable. concordance index (0.8499, 0.8497) area under curve (86.1%, 80.4%) showed satisfactory discriminative ability training test sets. could be effective reducing had few serious events.

Language: Английский

---

Nanotherapeutics in pulmonary infections

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 81 - 114

Published: Jan. 1, 2025

Language: Английский

---